Evidence map›Paper›PMID 25937844›Full record

ArticleJournal of neurodevelopmental disorders2014

A cross-sectional analysis of orienting of visuospatial attention in child and adult carriers of the fragile X premutation.

Ling M Wong, Naomi J Goodrich-Hunsaker, Yingratana A McLennan, Flora Tassone, Susan M Rivera, Tony J Simon

Open access · goldAbstract read
In one paragraph

Article in Journal of neurodevelopmental disorders, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 87% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Ling M WongDavis Medical Center, MIND Institute, University of California, Sacramento, CA 95817 USA ; War Related Illness and Injury Study Center, Veterans Affairs Medical Center, Washington, DC 20422 USA.
Naomi J Goodrich-HunsakerDavis Medical Center, MIND Institute, University of California, Sacramento, CA 95817 USA.
Yingratana A McLennanDavis Medical Center, MIND Institute, University of California, Sacramento, CA 95817 USA.
Flora TassoneDavis Medical Center, MIND Institute, University of California, Sacramento, CA 95817 USA ; Department of Biochemistry and Molecular Medicine, University of California, Davis Medical Center, Sacramento, CA 95817 USA.
Susan M RiveraDavis Medical Center, MIND Institute, University of California, Sacramento, CA 95817 USA ; Department of Psychology, University of California, Davis, CA 95616 USA ; Center for Mind and Brain, University of California, Davis, CA 95616 USA.
Tony J SimonDavis Medical Center, MIND Institute, University of California, Sacramento, CA 95817 USA ; Department of Psychiatry and Behavioral Sciences, University of California, Davis Medical Center, Sacramento, CA 95817 USA.
University of California, Davis · USUniversity of California Davis Medical Center · USVeterans Health Administration · US

Funding

Trajectories and Markers of Neurodegeneration in Fragile X Premutation CarriersR01MH078041 · NIMH · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HESSL, DAVID R, RIVERA, SUSAN M · 2007 to 2017
$5.4M
Development of targeted therapeutic agents for the treatment of FXTAS (2 of 6)RL1AG032119 · NIA · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HAGERMAN, PAUL J · 2007 to 2011
$4.1M
Neuro Therapeutics Research Institute (1 of 6)UL1DE019583 · NIDCR · UNIVERSITY OF CALIFORNIA AT DAVIS · PI HAGERMAN, PAUL J · 2008 to 2011
$3.0M
Fragile X Spectrum as Model for Neurogenetic Mechanisms of Cognitive DysfunctionRL1NS062412 · NINDS · UNIVERSITY OF CALIFORNIA AT DAVIS · PI SIMON, TONY J · 2007 to 2011
$2.7M
Interdisciplinary Training Program in Neurotherapeutics (6 of 6)TL1DA024854 · NIDA · UNIVERSITY OF CALIFORNIA AT DAVIS · PI CARTER, CAMERON S. · 2007 to 2011
$835k
NIA NIH HHS RL1 AG032119NIDA NIH HHS TL1 DA024854NIDCR NIH HHS UL1 DE019583NIMH NIH HHS R01 MH078041NINDS NIH HHS RL1 NS062412
6 · The paper itself

Abstract

backgroundFragile X premutation carriers (fXPCs) have an expansion of 55-200 CGG repeats in the FMR1 gene. Male fXPCs are at risk for developing a neurodegenerative motor disorder (fragile X-associated tremor/ataxia syndrome (FXTAS)) often accompanied by cognitive decline. Several broad domains are implicated as core systems of dysfunction in fXPCs, including perceptual processing of spatial information, orienting of attention to space, and inhibiting attention to irrelevant distractors. We tested whether orienting of spatial attention is impaired in fXPCs.

methodsParticipants were fXPCs or healthy controls (HCs) asymptomatic for FXTAS. In experiment 1, they were male and female children and adults (aged 7-45 years). They oriented attention in response to volitional (endogenous) and reflexive (exogenous) cues. In experiment 2, the participants were men (aged 18-48 years). They oriented attention in an endogenous cueing task that manipulated the amount of information in the cue.

resultsIn women, fXPCs exhibited slower reaction times than HCs in both the endogenous and exogenous conditions. In men, fXPCs exhibited slower reaction times than HCs in the exogenous condition and in the challenging endogenous cueing task with probabilistic cues. In children, fXPCs did not differ from HCs.

conclusionsBecause adult fXPCs were slower even when controlling for psychomotor speed, results support the interpretation that a core dysfunction in fXPCs is the allocation of spatial attention, while perceptual processing and attention orienting are intact. These findings indicate the importance of considering age and sex when interpreting and generalizing studies of fXPCs.

Indexed as

CueingEndogenousExogenousFMR1 geneFragile XFXTAS

Identifiers

PMID25937844
PMCPMC4416306
OpenAlexW2134951392

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.